Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033 ...
The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...
Too Old to Operate18 小时
Macular Oxygen Saturation and SCP Vascular Density in Diabetic Retinopathy
The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...
Australia’s TGA approves Apellis’ SYFOVRE for GA related to AMD
Pharmaceuticals announced that the Therapeutic Goods Administration, TGA, has approved SYFOVRE or pegcetacoplan, for the ...
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month ...
Impacts5 天
Advancements and Emerging Trends Shaping the Future of Electronic Health Records (EHR)
The landscape of healthcare is rapidly evolving, and at the center of this transformation is the Electronic Health Record ...
Macular Degeneration Treatment Market Size, Top Share, Forecast To 2033
Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...
Apellis Pharmaceuticals, Inc.: Apellis Receives Approval of SYFOVRE (pegcetacoplan) in ...
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...
Science Daily4 天
Eye Care News
Jan. 16, 2025 — A new report shows the benefit of wearing contact lenses for slowing myopia has a lasting effect -- good news since 50% of the world (5 billion people) will likely be nearsighted ...